RDNA randomized trial of 478 patients hospitalized for COVID-19 found that treatment with an inhaled form of heparin--which has antiviral and anti-inflammatory as well as anticoagulent properties--reduced the need for intubation by about half and reduced 28-day mortality by about two-thirds.
Summary: https://www.sciencedaily.com/releases/2025/09/250928095616.htm
Original paper: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00271-8/fulltext
Doctors tested a common drug on COVID. The results are stunning
Inhaled heparin significantly lowers the risk of death and ventilation in COVID-19 patients while also showing potential against other respiratory infections. With its unique triple-action benefits, it could serve as a powerful and accessible treatment worldwide.